S100B and LDH as parameters to monitor the clinical course of patients with advanced melanoma treated with Vemurafenib

DSpace Repository

Show simple item record

dc.contributor.advisor Eigentler, Thomas (PD. Dr. med.)
dc.contributor.author Abusaif, Sail Nawaf Rashid
dc.date.accessioned 2017-01-09T14:45:48Z
dc.date.available 2017-01-09T14:45:48Z
dc.date.issued 2016-12
dc.identifier.other 481588272 de_DE
dc.identifier.uri http://hdl.handle.net/10900/73928
dc.identifier.uri http://nbn-resolving.de/urn:nbn:de:bsz:21-dspace-739288 de_DE
dc.identifier.uri http://dx.doi.org/10.15496/publikation-15336
dc.description.abstract Vemurafenib is a highly efficient BRAF inhibitor for metastatic melanoma patients carrying the V600 mutation. Progression free survival is prolonged to approximately 6 months and 50 to 80% of the patients show objective tumor responses. S100B and LDH are established tumor markers in routine melanoma follow up. This study evaluated their potential as response and progression markers during vemurafenib treatment. A cohort of 44 patients with stage IV melanoma disease and treated with vemurafenib was retrospectively analyzed. Staging was performed every 6-8 weeks including CT scans, LDH and S100B. RECIST criteria were used for standardized radiological response evaluation. Correlation between response or progression, LDH and S100B was analyzed by accuracy tests, Spearman's rank correlation rho and polynomial regression analyses. There was a decent correlation between LDH and S100B decline and RECIST confirmed response especially in case S100B and/or LDH were elevated at baseline (accuracy 81.2% for S100B and 85.7% for LDH). Accuracy in case of RECIST confirmed progression and S100B/LDH was low with 32.4% for LDH and 30.3% for S100B. Neither polynomial regression analyses nor Spearman's rank correlation rho showed a correlation between the clinical course and S100B/LDH. S100B and LDH seem to predict tumor response with acceptable accuracy in early stages of the disease, especially for those patients with increased S100B and LDH levels at baseline. In this early phase of the disease CT scan intervals could be prolonged or scans could maybe omitted completely to reduce the radiation exposure without missing tumor progression. For detecting tumor progression in later phases of the disease both markers cannot substitute CT scans because of their inacceptable accuracy rates. en
dc.language.iso en de_DE
dc.publisher Universität Tübingen de_DE
dc.rights ubt-podok de_DE
dc.rights.uri http://tobias-lib.uni-tuebingen.de/doku/lic_mit_pod.php?la=de de_DE
dc.rights.uri http://tobias-lib.uni-tuebingen.de/doku/lic_mit_pod.php?la=en en
dc.subject.classification Melanom , Lactatdehydrogenase de_DE
dc.subject.ddc 500 de_DE
dc.subject.ddc 610 de_DE
dc.subject.other lactate dehydrogenase en
dc.subject.other metastatic melanoma en
dc.subject.other Response Evaluation Criteria In Solid Tumors en
dc.subject.other S100B en
dc.subject.other vemurafenib en
dc.title S100B and LDH as parameters to monitor the clinical course of patients with advanced melanoma treated with Vemurafenib en
dc.type PhDThesis de_DE
dcterms.dateAccepted 2016-10-04
utue.publikation.fachbereich Medizin de_DE
utue.publikation.fakultaet 4 Medizinische Fakultät de_DE
utue.publikation.source Melanoma Research, Band 23 (5), 2013, 396-401 de_DE


This item appears in the following Collection(s)

Show simple item record